Clone of homepage 4

Changemakers on a mission

The Anticancer Fund thinks differently, acts differently and prioritises the patients above all else.

We fill in the blanks spaces in cancer research, to deliver more and better treatments.

We empower patients with knowledge, and offer clear and reliable information about cancer and cancer treatments.

Be part of our mission. Consider your donation not just a contribution, but an investment.

Support us

Proud to join forces with scientists around the world

Our focus

Clinical Research

We make it happen

More can be done if financial returns are no longer the strategy when searching for new cures, but what patients need instead. Our research aims for treatments that significantly increase the survival and/or improve the quality of life of cancer patients.

Our research focus

Patient Information

We are here for you

Every patient has the right to get clear answers. We offer evidence-based information about your cancer and treatment. Please reach out to our free service My Cancer Navigator, if you have questions.

More about My Cancer Navigator

At a glance

29 ongoing clinical trials

1,6 million euros invested in research (in 2023)

90 scientific publications

1.466 patients supported (last 5 years)

Discover our latest news

Pancreatic cancer: early results of PROSPER-trial with repurposed medication show potential to improve outcomes

Researchers have completed the PROSPER trial, a clinical study examining whether two commonly available medications—propranolol and etodolac—could improve outcomes when administered around the time of pancreatic cancer surgery.

12 August 2025

Breaking new ground in bringing repurposed drugs to patients

The European Medicines Agency (EMA) has released findings from its Pilot Program on drug repurposing, marking a significant step toward establishing new regulatory pathways that could transform how existing medicines are developed for new therapeutic uses across Europe.

25 July 2025

Adaptive therapy shows promise in fighting drug-resistant cancer

New research published in the journal Cancer Research provides evidence that adaptive therapy represents a promising strategy to address one of oncology's challenges: drug resistance. Anticancer Fund is supporting clinical trials that explore this treatment approach, which offers a different perspective on how to treat cancer.

15 July 2025

FORCE consortium for more research in rare cancers

Joining a Europe-wide alliance to scale-up research on rare and hard-to-treat cancers

The Anticancer Fund is now part of FORCE, a major European initiative supporting research on rare and hard-to-treat cancers. Alongside 13 non-profit partners from 11 countries, we’re working to bring better, evidence-based treatments to patients who urgently need them.

3 June 2025